ABSTRACT
Context: Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. Objective: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in patients with inadequately controlled, eosinophilic asthma. Data sources: The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Study selection: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of reslizumab for the treatment of inadequately controlled, eosinophilic asthma. Data extraction: Two reviewers independently extracted and verified pre-defined data fields. Results: Four publications including 5 RCTs that compared reslizumab with placebo. For the comparison of reslizumab with placebo, asthma exacerbation (odds ratio (OR) = 0.46, 95% confidence interval (CI) = 0.35 to 0.59, p <0.00001); a forced expiratory volume in 1 s (FEV1) (the standardized mean difference (SMD) = 0.16, 95%CI = 0.10 to 0.23, p <0.00001); Asthma Control Questionnaire (ACQ) score (the SMD = −0.26, 95%CI= −0.36 to −0.16, p <0.00001); blood eosinophil counts (the SMD = −475.62, 95%CI = −528.41 to −422.83, p <0.00001). Safety assessments included the proportion of individuals who withdrawn due to adverse event (AE) (OR = 0.60 95%CI = 0.38 to 1.17, p = 0.16) indicated that reslizumab was well tolerated. Limitations: The article didn't research the safety, efficacy of reslizumab with longer term. Conclusions: This meta-analysis indicates that reslizumab to be an effective and safe treatment for inadequately controlled, eosinophilic asthma.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.